CSF-1 and its receptor in ovarian, endometrial and breast cancer.

The aim of this report is to review the role of CSF-1 and its receptor in neoplasms of the breast and female reproductive tract. Expression and function of CSF-1 and its receptor were studied in tumours of the human breast, ovary and endometrium. CSF-1 and its receptor, initially implicated as essential to normal monocyte development and trophoblastic implantation, have been more recently shown to be expressed by carcinomas of the breast, ovary and endometrium where activation of the receptor by ligand produced either by the tumour cells or by stromal elements stimulates tumour cell invasion by a urokinase-dependent mechanism. Breast carcinomas express wild-type CSF-1 receptors at levels comparable to those observed in trophoblast and monocytes. Ovarian and endometrial carcinomas express significantly lower levels of wild-type, functional CSF-1Rs while ovarian carcinomas also express unusual transcripts which diverge from the wild-type CSF-1R transcript in their 5' extracellular and other sequences. Tumour cell expression of CSF-1R is under the control of several steroid hormones (glucocorticoids and progestins) and tumour cell CSF-1 expression appears to be regulated by other hormones, some of which are involved in normal lactogenic differentiation. In addition, tumour cells often produce CSF-1 at such high levels that CSF-1 spills into the extracellular fluid and circulation. Measurements of circulating levels of CSF-1 have proved useful in patients with ovarian, endometrial and breast carcinoma patients both for disease detection and monitoring of response to breast carcinoma patients both for disease detection and monitoring of response to therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  M. Duffy,et al.  Urokinase plasminogen activator and prognosis in breast cancer , 1990, The Lancet.

[2]  L. Yee,et al.  Oncogene structure, function, and expression in breast cancer. , 1989, Seminars in diagnostic pathology.

[3]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[4]  Inder M. Verma,et al.  Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus , 1986, Nature.

[5]  F. Beuvon,et al.  Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. , 1994, Journal of the National Cancer Institute.

[6]  F. Beuvon,et al.  Expression of Colony‐Stimulating Factor‐1 and Its Receptor (the Protein Product of c‐fms) in Invasive Breast Tumor Cells , 1993, Annals of the New York Academy of Sciences.

[7]  P. Nowell,et al.  Origins of human cancer revisited , 1990, Cell.

[8]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[9]  T. Tong,et al.  Cancer statistics, 1991 , 1991, CA: a cancer journal for clinicians.

[10]  J. Horiguchi,et al.  CSF-1 and C-FMS gene expression in human carcinoma cell lines. , 1988, Biochemical and biophysical research communications.

[11]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[12]  L. Rohrschneider,et al.  Activation of the feline c-fms proto-oncogene: Multiple alterations are required to generate a fully transformed phenotype , 1988, Cell.

[13]  B. Kacinski,et al.  Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. , 1995, Oncogene.

[14]  T. Pawson,et al.  The unique insert of cellular and viral fms protein tyrosine kinase domains is dispensable for enzymatic and transforming activities. , 1989, The EMBO journal.

[15]  Robert A. Edwards,et al.  Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. , 1989, The Yale journal of biology and medicine.

[16]  B. Binder,et al.  Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. , 1992, Cancer research.

[17]  C. Willman,et al.  Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1 , 1989, The Journal of experimental medicine.

[18]  L. Lagasse,et al.  Prognosis and treatment of endometrial cancer. , 1980, American journal of obstetrics and gynecology.

[19]  W. Halsted I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. , 1907, Annals of surgery.

[20]  S. Chambers,et al.  Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro , 1994, Steroids.

[21]  J. Downing,et al.  A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential , 1988, Cell.

[22]  W. Wiktor-Jedrzejczak,et al.  A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility. , 1991, Developmental biology.

[23]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[24]  A. Balmain,et al.  Is colony‐stimulating factor‐1 a key mediator of breast cancer invasion and metastasis? , 1993, Molecular carcinogenesis.

[25]  D. Stern,et al.  EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.

[26]  A. Harris,et al.  Epidermal growth factor receptors in human breast cancer. , 1988, Cancer treatment and research.

[27]  F. Galibert,et al.  Nucleotide sequence and structural organization of the human FMS proto-oncogene. , 1989, Oncogene research.

[28]  D. Stern,et al.  Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Ariza,et al.  The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients. , 1990, International journal of radiation oncology, biology, physics.

[30]  B. Kacinski,et al.  Expression of transcripts for CSF-1 and for the "macrophage" and "epithelial" isoforms of the CSF-1R transcripts in human ovarian carcinomas. , 1994, Cancer detection and prevention.

[31]  N. Deng,et al.  Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines. , 1992, Cancer research.

[32]  S K Chambers,et al.  Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. , 1993, American journal of obstetrics and gynecology.

[33]  U. Puistola,et al.  Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125 and the aminoterminal propeptide of type III procollagen. , 1995, American journal of obstetrics and gynecology.

[34]  B. Kacinski,et al.  The first intron of human c-fms proto-oncogene contains a processed pseudogene (RPL7P) for ribosomal protein L7. , 1994, Genomics.

[35]  L. Yee,et al.  FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. , 1991, Oncogene.

[36]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[37]  M. Roussel,et al.  Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. , 1986, The Journal of clinical investigation.

[38]  J. Pollard,et al.  Colony stimulating factor-1 stimulates Ishikawa cell proliferation and lipocortin II synthesis , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  F. Beuvon,et al.  Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells? , 1990, Journal of cellular biochemistry.

[40]  R. Camplejohn,et al.  Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Robert A. Edwards,et al.  High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. , 1988, International journal of radiation oncology, biology, physics.

[42]  R. Arceci,et al.  Apparent role of the macrophage growth factor, CSF-1, in placental development , 1987, Nature.

[43]  L. Yee,et al.  Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. , 1990, The American journal of pathology.

[44]  P Roth,et al.  The biology of CSF-1 and its receptor. , 1992, Current topics in microbiology and immunology.

[45]  D. Carter,et al.  NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. , 1992, Gynecologic oncology.

[46]  P. Schwartz,et al.  Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. , 1989, International journal of radiation oncology, biology, physics.

[47]  M. Schmitt,et al.  UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER , 1989, The Lancet.

[48]  H. Koeppen,et al.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Stern,et al.  The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Bast,et al.  Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. , 1989, The Journal of clinical investigation.

[51]  R. Kriz,et al.  Human CSF-1: molecular cloning and expression of 4-kb cDNA encoding the human urinary protein. , 1987, Science.

[52]  Rutledge Fn,et al.  Epithelial carcinoma of the ovary:prognostic importance of histologic grade. , 1975 .

[53]  D. Carter,et al.  Expression of neu Antigen in Normal Lactating and Prepartum Mammary Epithelial Cells , 1995, The Journal of the Society for Gynecologic Investigation: JSGI.